California Life Sciences Association (CLSA) and Congressman Scott Peters Announce Support for New Legislation to Repeal Medical Device Tax

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

California Life Sciences Association (CLSA), the trade association representing Californias life sciences sector, joined with Congressman Scott Peters (D-San Diego) to issue the following statements announcing support for the reintroduction of the Protect Medical Innovation Act of 2019 (H.R. 2207), bipartisan legislation that fully repeals the 2.3% excise tax levied on medical device firms as part of the Affordable Care Act.

According to CLSAs newly released 2019 California Life Sciences Industry Report, California is home to 1,848 medical device firms employing over 81,000 people “ more firms and employees than any other state in the nation “ making the impact of the tax on California particularly troublesome. Visit CLSAs Digital Action Center to learn more about the tax.

Statement from CLSA President & CEO Mike Guerra

California Life Sciences Association (CLSA) welcomes the introduction of legislation that once-and-for-all repeals the ill-conceived 2.3% medical device excise tax. Since its inception, this tax has only hindered investment in medical technology research and development in California and throughout the U.S. For many years, our trade association has consistently led the charge in educating the California Congressional delegation on the perils of this tax on innovation. With over 226 bipartisan cosponsors in the House, including 22 bipartisan members of Californias delegation in the House of Representatives, this bill has broad, bipartisan support. CLSA and our extensive statewide membership of biomedical innovators welcome the introduction of this device tax repeal legislation. We will continue to work diligently with our bipartisan California Congressional delegation until this tax is fully repealed.

Statement from Congressman Scott Peters (D-San Diego), Member of House Energy & Commerce Committee:

San Diegos medical device industry fuels innovation in our burgeoning life sciences cluster, but the medical device tax prevents them from investing in their next venture. Ive led the charge to repeal the medical device tax to eliminate this barrier and foster the development of new technology that will improve and save lives. That creates jobs in San Diego and brings more life-saving technology to patients. Thank you to California Life Sciences Association (CLSA) for their support of these entrepreneurs and everyone who depends on medical devices to maintain their quality of life.

Visit CLSAs Digital Action Center to contact your Member of Congress or to learn more about the tax.

  • Learn More about the California life sciences sector
  • View CLSAs Legislative Action Center
  • Watch CLSAs Faces of California Biomedical Innovation Web Series
  • View CLSAs Advocacy Priorities
  • View upcoming CLSA events
  • Meet the CLSA Board of Directors

About California Life Sciences Association (CLSA)

California Life Sciences Association (CLSA) is the states largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow Californias life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciencesFacebookInstagramLinkedIn and YouTube.

Media Contact:
California Life
Sciences Association (CLSA)
Will Zasadny | Director, Communications
[email protected]
| 619-961-8848